B. Bringeon

发表

Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival

F. Rocher, S. Chabaud, P. Pommier, 2021, Journal of contemporary brachytherapy.